CagriSema to investigate efficacy in reducing **Type 2 Diabetes** and **Painful Diabetic Peripheral Neuropathy** symptoms

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia, often leading to severe complications. One such debilitating complication is Painful Diabetic Peripheral Neuropathy (DPN), affecting nerve function and causing chronic pain, numbness, and tingling, significantly impairing quality of life. Current treatments for DPN primarily manage symptoms, with limited options addressing the underlying pathology or offering substantial pain relief. The need for novel therapies that can simultaneously improve glycemic control and alleviate DPN symptoms remains a critical unmet medical need. CagriSema, a co-agonist targeting both GLP-1 and amylin receptors, holds promise due to its known effects on glucose homeostasis, weight loss, and potential neuroprotective properties.

This is a planned, randomized, placebo-controlled clinical trial designed to investigate the effects of CagriSema in individuals diagnosed with both Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy. Participants will be randomly assigned to receive either the active investigational medicine, CagriSema, or a placebo. The study duration for each participant is approximately 10 months. Specific details regarding the dose, route of administration, frequency, or primary endpoints are not yet publicly available, as the study is not yet recruiting. The trial aims to compare the outcomes between the active treatment and placebo arms.

No results are available as this study is currently listed as 'NOT_YET_RECRUITING' and is scheduled to begin in August 2026. Therefore, no findings, statistical data, or specific outcomes can be reported at this time.